Rabbit monoclonal antibodies are produced by immunizing rabbits and harnessing the power of hybridoma technology. The process begins with exposing rabbits to target antigens, prompting a diverse immune response. Subsequently, B cells from the rabbit’s spleen are fused with myeloma cells, creating hybridomas that can continuously produce monoclonal antibodies. Through careful cloning, NeoBiotechnologies ensure a consistent population of identical antibody-producing cells.
Our rabbit monoclonal antibodies display high affinity and specificity, making them particularly effective in critical applications like immunohistochemistry and flow cytometry, where a strong and specific binding interaction is paramount. These antibodies also hold promise in therapeutic applications due to their potential for reduced immunogenicity in humans compared to fully murine antibodies. Neobiotechnologies prioritizes the development of antibodies that meet therapeutic standards, and rabbit monoclonal antibodies emerge as valuable tools in this pursuit.
